In addition to general security, the effectiveness will be assessed by a change from baseline in the average number of micturitions or urinations per day, as assessed by a patient diary at 12 months, plus a 48-month long-term evaluation. The trial is expected to complete the registration in 2008.
In September 2007, Tengion announced the successful completion of enrollment of a phase 2 clinical trial of the Neo – bladder Augment for neurogenic bladder due to spina bifida and the initiation of a phase 2 clinical trial of the Neo – bladder Augment for neurogenic bladder due to spinal cord injury.. A plurality of pharmacotherapy options in the treatment of OAB tries been, with varying success. And compatibility have failed.nce of either symptom improvement or ability to tolerate pharmacotherapy used aggressive measures, including the investigational injection of botulism toxin , is neurostimulation or surgical procedures.Courtesy can the total daily Women ‘s Health Policy Report see looking for and, or log in. For email for delivery here to emphatically the daily Women’s Health policy coverage free service is provided which National Partnership for Women & Families from the Advisory Board Company published.